Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure


Creative Commons License

Korobelnik J., Loewenstein A., Eldem B., Joussen A. M., Koh A., Lambrou G. N., ...More

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, vol.259, no.3, pp.567-574, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 259 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.1007/s00417-021-05097-0
  • Journal Name: GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.567-574
  • Keywords: Retinal disease, Ophthalmology, COVID-19, Coronavirus, Recommendations, Vision Academy, RANIBIZUMAB
  • Hacettepe University Affiliated: Yes

Abstract

Purpose Following the first wave of the COVID-19 pandemic in early 2020, the easing of strict measures to reduce its spread has led to a resurgence of cases in many countries at both the national and local level. This article addresses how guidance for ophthalmologists on managing patients with retinal disease receiving intravitreal injections of anti-vascular endothelial growth factor (VEGF) during the pandemic should be adapted to the local epidemic pressure, with more or less stringent measures implemented according to the ebb and flow of the pandemic.